Steroid sidestep: Evading androgen ablation by abiraterone - Abstract

Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined.

Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer (CRPC).

Written by:
Sharifi N.   Are you the author?
Cancer Biology, Cleveland Clinic.  

Reference: Clin Cancer Res. 2014 Nov 28. pii: clincanres.2899.2014.
doi: 10.1158/1078-0432.CCR-14-2899


PubMed Abstract
PMID: 25432158

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe